Healthcare of Ontario Pension Plan Trust Fund Cuts Position in Xeris Biopharma Holdings, Inc. $XERS

Healthcare of Ontario Pension Plan Trust Fund decreased its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 13.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 464,084 shares of the company’s stock after selling 73,399 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Xeris Biopharma were worth $2,692,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in XERS. Apella Capital LLC increased its holdings in Xeris Biopharma by 2,359.0% in the fourth quarter. Apella Capital LLC now owns 245,897 shares of the company’s stock valued at $1,930,000 after buying an additional 235,897 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Xeris Biopharma by 13.8% during the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after acquiring an additional 1,358,760 shares during the period. Granahan Investment Management LLC boosted its stake in shares of Xeris Biopharma by 249.4% during the 4th quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock worth $9,604,000 after acquiring an additional 873,236 shares in the last quarter. Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Xeris Biopharma during the 1st quarter worth approximately $1,204,000. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of Xeris Biopharma in the 4th quarter worth approximately $689,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Insider Activity at Xeris Biopharma

In other Xeris Biopharma news, insider Steven Pieper sold 27,600 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $8.52, for a total value of $235,152.00. Following the sale, the insider owned 1,366,053 shares of the company’s stock, valued at $11,638,771.56. This represents a 1.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $97,440.00. Following the completion of the sale, the director directly owned 126,500 shares in the company, valued at $770,385. This trade represents a 11.23% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 234,833 shares of company stock valued at $1,742,622 in the last quarter. 4.35% of the stock is owned by corporate insiders.

Xeris Biopharma Trading Down 4.0%

NASDAQ:XERS opened at $8.08 on Friday. Xeris Biopharma Holdings, Inc. has a 52-week low of $4.87 and a 52-week high of $10.08. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The stock has a fifty day simple moving average of $7.51 and a 200-day simple moving average of $6.79. The company has a market capitalization of $1.39 billion, a PE ratio of 134.67 and a beta of 0.62.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The firm had revenue of $83.13 million for the quarter, compared to analysts’ expectations of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. On average, equities research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.